SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

GB Sciences Inc. – ‘8-K’ for 8/25/22

On:  Tuesday, 8/30/22, at 3:23pm ET   ·   For:  8/25/22   ·   Accession #:  1437749-22-21498   ·   File #:  0-55462

Previous ‘8-K’:  ‘8-K’ on 3/16/22 for 3/15/22   ·   Next:  ‘8-K’ on 3/10/23 for 3/9/23   ·   Latest:  ‘8-K’ on 9/8/23 for 9/1/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/30/22  GB Sciences Inc.                  8-K:3       8/25/22   11:134K                                   RDG Filings/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     21K 
 6: R1          Document And Entity Information                     HTML     41K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- gblx20220830_8k_htm                 XML     12K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.DEF  XBRL Definitions -- gblx-20220825_def                XML     34K 
 4: EX-101.LAB  XBRL Labels -- gblx-20220825_lab                     XML     43K 
 5: EX-101.PRE  XBRL Presentations -- gblx-20220825_pre              XML     33K 
 2: EX-101.SCH  XBRL Schema -- gblx-20220825                         XSD     14K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    18K 
11: ZIP         XBRL Zipped Folder -- 0001437749-22-021498-xbrl      Zip     12K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C: 
 i false  i 0001165320 0001165320 2022-08-25 2022-08-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
 
FORM  i 8-K
 
CURRENT REPORT
Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  i August 25, 2022
 
 i GB Sciences, Inc.
(Exact name of Registrant as specified in its charter)
 
 
 i Nevada
(State or other Jurisdiction of
Incorporation or organization)
(Commission File Number)
 i 59-3733133
(IRS Employer I.D. No.)
 
 i 3550 W. Teco Avenue
 i Las Vegas,  i Nevada  i 89118
(Address of Principal Executive Offices) (Zip Code)
 
 i (866)  i 721-0297
Registrant’s telephone number, including area code)
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 i                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
                  
 i                     Soliciting material pursuant to Rule l 4a- l 2 under the Exchange Act ( 17 CFR 240. l 4a- l 2)   
                
 i                     Pre-commencement communications pursuant to Rule l 4d-2(b) under the Exchange Act (17 CFR 240. l 4d-2(b)) 
                  
 i                     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. l 3e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
None
N/A
N/A
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  i 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
 
 
 
Item 3.02 Unregistered Sales of Equity Securities.
 
On August 25, 2022, the Registrant (the “Company”) issued options (the “Options”) to a total of seven persons which include the officers and directors of the Company, who will be instrumental in obtaining an up-listing of the common shares of the Company onto the NASDAQ Stock Market. The Options will vest on the effective date of the up-listing (the “Effective Date”), and will equal options sufficient to purchase 13% of the issued and outstanding common shares of the Company on a fully diluted basis, as of the Effective Date. The exercise price of one Option will equal 80% of the value of one share of common stock on the Effective Date.
 
The Options were not registered under the Act and were issued in reliance upon the exemption from registration contained in Section 4(2) of the Act. The securities, as well as the shares underlying the Options, may not be reoffered or sold in the United States by the holders in the absence of an effective registration statement, or valid exemption from the registration requirements of the Act.
 
SIGNATURE PAGE
 
Pursuant to the requirement of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
               GB Sciences, Inc.
                   a Nevada corporation
 
         
 
By:
 
       
     
Chief Executive Officer
 
 
 

Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on:8/30/22None on these Dates
For Period end:8/25/22
 List all Filings 
Top
Filing Submission 0001437749-22-021498   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 19, 10:31:04.1pm ET